complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.

Author: Yom Faemi
Country: Peru
Language: English (Spanish)
Genre: Spiritual
Published (Last): 23 August 2009
Pages: 479
PDF File Size: 8.68 Mb
ePub File Size: 3.53 Mb
ISBN: 985-6-42783-995-5
Downloads: 68203
Price: Free* [*Free Regsitration Required]
Uploader: Nirisar

Epirubicin and its major metabolites are excreted through biliary excretion and to a lesser extent urinary excretion. Additionally, the free radicals crosslink sulfhydryl groups of calcium-release channels and inhibit Ca-ATPase which leads to extensive depletion of sarcoplasmic reticulum SR calcium stores and prevents restoration of calcium stores in the SR, respectively.

There was a problem providing the content you requested

If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage. Epirubicin-induced free radical formation contributes to its eoxorrubicina. Unfortunately, trifluoperazine and verapamil must be given in toxic doses to achieve this positive effect. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: The immune response of the immunocompromised patient to vaccines is decreased and higher doses or more frequent boosters may be required.

It is not known if epirubicin is excreted in human breast milk but has been detected in breast milk of animals.

Doxorrubicina – Viquipèdia, l’enciclopèdia lliure

While the spectrum of toxicities for epirubicin and doxorubicin are similar, the incidence of toxicity differs. Dosage For the adjuvant treatment of breast cancer: Valspodar is an investigational cyclosporine analog with less renal and immunosuppressive effects than cyclosporine while retaining effects on MDR. The decreased incidence of clinically significant cardiac toxicity associated with epirubicin as compared to doxorubicin is due to the more rapid clearance of mevanismo and possibly, glucuronidation of epirubicin.


Signs and symptoms of anaphylactic reactions include skin rash unspecifiedpruritus, fever, chills and anaphylactic shock. The common dose for bladder cancer prophylaxis following TUR is epirubicin 50 mg in 50 ml sterile normal saline instilled into the bladder once weekly for 4 weeks then maintenance treatement of the same dose monthly for 11 months.

Because antineoplastic agents exert their toxic effects against rapidly growing cells, such as hematopoietic progenitor cells, sargramostim, GM-CSF, and filgrastim, G-CSF, are contraindicated for use in patients within 24 hours of treatment with antineoplastic agents. It is prudent to closely monitor patients for loss of clinical efficacy of digoxin while acciln antineoplastic therapy. This reaction causes erythema, exfoliative dermatitis, pain, and burning, similar to that experienced with the original radiation therapy.

Epirubicin should not be administered during pregnancy because of the possibility of teratogenic effects. It is characterized by facial flushing and delayed erythematous streaking along the vein.

It does not appear dexrazoxane affects the clinical efficacy or non-cardiac toxicity of epirubicin. Patients with hepatic impairment: A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

If a woman becomes pregnant during therapy, she should be advised of the potential risks to the fetus. These reactions are acdion with excessively rapid administration and do not contraindicate further use.

A second woman with breast cancer metastatic to the liver received fluorouracil, cyclophosphamide and epirubicin but was removed from the trial due to the pregnancy. The suggested maximum tolerated dose MTD for epirubicin, which is dependent on performance status, other chemotherapy agents or radiation given in combination, and disease state, is as follows: She received the last dose at 34 weeks of the pregnancy and delivered a healthy baby at 35 weeks.

Despite these dose increases, the immune response may still be suboptimal.

Use care to avoid accidental exposure to epirubicin during preparation, handling, and administration. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: When administered to pediatric patients, doxorubicin may contribute to prepubertal growth inhibition. Epirubicin-induced cardiomyopathy and congestive heart failure CHF is associated with the cumulative dose of epirubicin.


The majority of patients were then able to undergo surgical resection.

Signs of myelosuppression include pancytopenia, leukopenia, neutropenia, thrombocytopenia, and anemia. Several compounds including cyclosporine, cyclosporine analogs and verapamil may block this protein and reverse resistance.

In addition, epirubicin has a lower incidence of cardiotoxicity; the maximum cumulative dose is almost twice that of doxorubicin.

Patients who have received prior mitoxantrone therapy may also experience increased cardiotoxicity. These complexes have high association constants and may contribute to epirubicin-induced cardiotoxicity by enhancing redox cycling to produce membrane and mitochondria damage. Epirubicin has been designated an orphan drug by the FDA for this indication. These changes do not necessitate dose modification or discontinuation and are not predictive of delayed cardiotoxicity.

J Clin Oncol ; Dodorrubicina examining the use of the r-isomer of verapamil to block MDR, which has less cardiac effects, are underway. Symptoms may doxorfubicina up to an hour and may be treated with steroids, antihistamines and ice packs. Men may experience spermatogenesis inhibition.

mecanismo de acción de antineoplasicos by angel vasquez garcia on Prezi

The dose of epirubicin should be adjusted for elevations in the total bilirubin or AST because these patients will have a decreased clearance of epirubicin with an increase in overall toxicity see Dosage.

Attempt doxorrhbicina aspirate the drug prior to removing the needle. Patients with pre-existing bone marrow suppression or tumor involvement of the bone marrow may require lower starting doses e.